Securities and Exchange Board of India (SEBI) signed off on 13 initial public offerings (IPOs), including Urban Company and BoAt’s parent Imagine Marketing, facilitating fresh fundraises of nearly ₹15,000 crore in the next few months.

SEBI IPO Approvals Drive Market Momentum

SEBI (Securities and Exchange Board of India), situated in Mumbai, is the market regulator that controls the securities and capital market of India. The main functions of the Company are to safeguard investor rights, manage the securities market, and promote the raising of funds through the issue of shares.

In performing its duties, SEBI is reported to have given a nod to 13 IPOs. The primary market is thus drawn into action, and there is a prospect of ₹15,000 crore of capital coming in.

Key Highlights of Approved IPOs

The list of IPOs just approved includes the names of prominent consumer-focused companies such as Urban Company, a rapidly growing Indian home services marketplace, and Imagine Marketing, the parent company of BoAt, the Indian leader in wearables and audio products.

Urban Company is aiming to gather about ₹1,900 crores through the issuance of a mix of new equity shares as well as an offer for sale. The company, which is backed by top investors, is completing its IPO preparations for the last week of this month.

Also Read: Urban Company IPO Price Band Fixed at ₹98-103

On the other hand, Imagine Marketing who went in for a confidential filing of the draft papers in April 2025 has officially got the approval for the second IPO after the company decided to ditch its 2022 plan. It is predicted that the public issue will be welcomed by a strong retail and institutional investor audience given the company’s position in the smart wearables and consumer electronics field.

The others that have found their name on the list SEBI clearance for are:

• Juniper Green Energy

• Jain Resource Recycling

• Ravi Infrabuild Projects

• Mouri Tech

• Allchem Lifescience

• Omnitech Engineering

• KSH International

• Pace Digitek

• Priority Jewels

• Corona Remedies

• Om Freight Forwarders

This is just about one of the most weeks with numerous IPO approvals in recent times.

Also Read: Upcoming IPOs in September: Market Set for Action

Growing Pipeline of IPO Approvals

Most of these companies submitted their draft red herring prospectuses (DRHPs) between March and June, showing the walk of India’s equity markets.

The jump in the number of given approvals happens when the primary market is very lively, and investors are very keen to participate. To exemplify, in August 2025 alone:

• 12 companies started trading on main exchanges.

• 34 SMEs were listed on SME platforms.

In July, 13 more companies went public on the main board.

As per the data from SEBI, there are over 70 companies such as Lenskart, Hero Motors, Indira IVF, and Canara Robeco Asset Management waiting for the nod to IPO. The combined potential of these firms to gather close to ₹1.4 trillion on approval is anticipated.

Implications for India’s Capital Market

The flood of IPO approvals sends the message that SEBI is striving for faster actions and is concentrated on not letting any queues of IPO resolutions. This step is sanctioned to raise money supply, diversify investors’ choices, and give firms the opportunity to expand their business.

The coming of such big names as the sister company of Urban Company and BoAt’s parent Imagine Marketing is bound to create a highly attractive basket of consumer, technology, and lifestyle stocks for investors.

IPO Market Outlook 2025

Projections from the industry point to a bright future for the Indian IPO market, reflected in:

• Growing participation of retail investors in the equity markets.

• Rising inflows of foreign institutional investments (FIIs).

• Range of sectors from renewables to technology.

• The demand for consumer and lifestyle brands such as BoAt is very strong and this trend will continue.

This will mark the primary market as a significant instrument for drawing capital for the remainder of FY25, with an unlocked fundraising potential of almost ₹15,000 crore through these 13 approvals.

Impact of Market and SEBI IPO Approvals

The SEBI IPO decisions from the regulator show that it trusts India’s capital markets very much. The regulator’s green light for companies such as Urban Company and BoAt’s parent carves out a large investor base and guarantees the continuity of capital raising in the next quarters.

The waiting list is never going to be empty, and there are more than 70 companies in the pipeline for IPOs, meaning that the SEBI IPO approvals will still be the main factor to drive the stock market in India, and this will make 2025 one of the years with the most capital raising activities in the country.

FAQ’s

READ MORE ON

Read the full article here: SEBI Approves IPO Proposals of 13 Companies — For more updates, visit Wittiya – Top Business News, Stock Market Insights & Financial Updates (Wittiya).

Allchem Lifescience, a Gujarat-based manufacturer of API intermediates and specialty chemicals, has filed draft papers with SEBI for an IPO worth ₹190 crore. The IPO consists of a fresh issue of equity shares worth ₹130 crore for debt repayment and corporate needs, along with an offer for sale (OFS) of 71.55 lakh shares by promoters.

Gujarat-based Allchem Lifescience, a manufacturer specializing in active pharmaceutical ingredient (API) intermediates and specialty chemicals, has filed draft papers with the Securities and Exchange Board of India (SEBI) for its ₹190 crore Initial Public Offering (IPO).

The IPO includes a fresh issue of equity shares worth ₹130 crore, which will primarily be used for debt repayment and general corporate expenses. Additionally, 71.55 lakh equity shares will be offered for sale (OFS) by promoters Kantilal Ramanlal Patel and Manisha Bipin Patel.

Founded in 2017, Allchem Lifescience has developed the capability to manufacture 263 products across various organic chemistries. The company is known for producing piperazine derivatives, key raw materials for APIs such as quetiapine, used in treating schizophrenia and bipolar disorder. Its manufacturing facility is located in Vadodara, Gujarat, and its client base includes major pharmaceutical companies like Alembic Pharmaceuticals, Indoco Remedies, and Neuland Laboratories.

Financially, the company’s revenue grew at a compound annual growth rate (CAGR) of 12.75% between FY22 and FY24, with a revenue of ₹7.84 crore for the six months ending September 30, 2024. Profit after tax (PAT) grew at a CAGR of 28.65% during the same period, reaching ₹1.09 crore for the six months ending September 2024.

Emkay Global Financial Services is the sole book-running lead manager for the IPO. Investors will be closely watching this offering as the company looks to expand its operations in the growing specialty chemicals and API market.

Read the full article here: Allchem Lifescience’s ₹190 Crore IPO Set to Boost Pharma Sector! — For more updates, visit Wittiya – Top Business News, Stock Market Insights & Financial Updates (Wittiya).

Allchem Lifescience Limited has filed its draft papers with SEBI for an IPO to raise ₹190 crore through a fresh issue. The company, specializing in active pharmaceutical ingredients and specialty chemicals, has shown consistent financial growth. The IPO proceeds will be used for debt repayment and business expansion.

Allchem Lifescience Limited, a key player in the pharmaceutical and specialty chemicals sector, has filed its Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) for an initial public offering (IPO).

Company Overview

Founded in 2017, Allchem Lifescience specializes in active pharmaceutical ingredients (API) intermediates and specialty chemicals. The company plays a crucial role in manufacturing piperazine derivatives, essential for producing drugs like Quetiapine. With a reaction volume of 1,134 KL and a hydrogenation capacity of 60 KL, it ranks among India’s top producers, according to a CARE Ratings report.

Allchem serves both domestic and international clients, including Alembic Pharmaceuticals, Micro Labs, Indoco Remedies, Neogen Chemicals, and MSN Laboratories, among others.

Financial Performance

The company has shown consistent growth in recent years:

• Revenue grew at a CAGR of 12.75% from FY22 to FY24.
• Revenue figures:
  • ₹784.48 million (six months ending September 2024)
  • ₹1,374.21 million (FY24)
  • ₹1,057.19 million (FY23)
  • ₹1,081.01 million (FY22)
• Profit after tax (PAT) grew at a CAGR of 28.65% from March 2022 to March 2024.

IPO Details

The IPO consists of:

• A fresh issue of equity shares worth ₹190 crore (face value ₹10 each).
• An offer for sale (OFS) of up to 7,155,000 equity shares.

The OFS includes:

• 3,577,500 shares from Kantilal Ramanlal Patel.
• 3,577,500 shares from Manisha Bipin Patel.

Utilization of Funds

Allchem Lifescience plans to use approximately ₹130 crore from the IPO proceeds for:

• Repayment or prepayment of existing borrowings.
• General corporate purposes and business expansion.

Emkay Global Financial Services Ltd is the sole book-running lead manager for the IPO.

Read the full article here: Allchem Lifescience IPO: A Golden Investment Opportunity? — For more updates, visit Wittiya – Top Business News, Stock Market Insights & Financial Updates (Wittiya).